ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: As is evident from previous work with BCR-ABL kinase inhibitors for chronic myeloid leukemia and in other kinase-targeted therapies, understanding mechanisms of drug resistance is a crucial first step in developing strategies to prevent or overcome it42, 43.